By Liam Takahashi, Project Engineer, and Scott Merz, Business Development Manager, Asahi Kasei Bioprocess America, Inc.
Precise scale-up of oligonucleotide therapies is crucial to achieve success at a mass manufacturing level. While these therapies represent an important part of the greater biopharmaceutical portfolio, the challenges inherent to their scale-up require technology solutions that are easily integrated to processes, fit-to-purpose, and optimized to mitigate the potential for failure.
Demand for cGMP oligonucleotides continues to increase as RNA and DNA therapeutics advance through clinical trials. In order to reduce manufacturing costs and increase product yields for these therapies, Asahi Kasei Bioprocess America (AKBA) has developed a suite of manufacturing-scale equipment designed to help developers seamlessly scale their products from research to commercial validation. Its Static Compression Synthesis (SCS) Columns represent the latest advancements in synthesis columns for this scale-up, offering users a simplified, state-of-the-art technology solution that allows them to transition from research scale to clinical and commercial scale with ease.